Journal of Research in Pharmacy Practice

Rational use of medicine in the pediatric age group: A summary on the role of clinical pharmacists

Document Type : Original Article

Authors

. Roya Kelishadi
. Firoozeh Mousavinasab

Pediatrics Department, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract
Medication errors (ME) and adverse drug reactions still continue to be the important 
factors for out- and in-patient treatments. MEs are critical troubles in all hospitalized 
populations that can increase length of hospital stay, expenses, mortality and morbidity. In 
many countries, clinical pharmacists have been involved in reducing MEs from years ago. 
A growing body of evidence suggests that pharmacist interventions have major impact on 
reducing MEs in pediatric patients, thus improving the quality and efficiency of care provided. 
This paper presents a literature review on the role of clinical pharmacists in reducing MEs, 
and underscores the importance of pharmacist-physician-patient collaboration for all patients 
notably in the pediatric age group.

Keywords

Clinical pharmacy
medication error
children
prevention
  1. Waldman JD, Smith HL. Strategic planning to reduce medical 
    errors: Part I−diagnosis. J Med Pract Manage 2012;27:230-6. 
    2. Kohn LT, Corrigan JM, Donaldson MS To Err is Human: 
    Building a Safer Health System. Washington, DC: National 
    Academy Press; 1999.
    3. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. 
    Adverse drug events in hospitalized patients. Excess 
    length of stay, extra costs, and attributable mortality. JAMA 
    1997;227:301-6.
    4. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, 
    et al. Incidence of adverse drug events and potential adverse 
    drug events: Implications for prevention. JAMA 1995;274:29-34.
    5. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, 
    Gallivan T, et al. Systems analysis of adverse drug events. 
    ADE Prevention Study Group. JAMA 1995;274:35-43.
    6. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, 
    et al. The costs of adverse drug events in hospitalized patients. 
    Adverse Drug Events Prevention Study Group. JAMA 
    1997;277:307-11.
    7. Bates DW, Boyle DL, Vander Vliet MB, Schneider J, Leape LL. 
    Relationship between medication errors and adverse drug 
    events. J Gen Intern Med 1995;10:199-205.
  2. 8. Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, 
    Lawthers AG, et al. Incidence of adverse events and negligence 
    in hospitalized patients: Results of the Harvard Medical 
    Practice Study I. N Engl J Med 1991;324:370-6.
    9. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, 
    Barnes BA, et al. The nature of adverse events in hospitalized 
    patients: Results of the Harvard Medical Practice Study II. N 
    Engl J Med 1991;324:377-84.
    10. Cohen V, Jellinek SP, Hatch A, Motov S. Effect of clinical 
    pharmacists on care in the emergency department: a 
    systematic review. Am J Health Syst Pharm 2009;66:1353-61.
    11. von Laue NC, Schwappach DL, Koeck CM. The epidemiology 
    of preventable adverse drug events: a review of the literature. 
    Wien Klin Wochenschr 2003;115:407-15.
    12. Klopotowska JE, Kuiper R, van Kan HJ, de Pont AC, Dijkgraaf 
    MG, Lie-A-Huen L, et al. On-ward participation of a hospital 
    pharmacist in a Dutch intensive care unit reduces prescribing 
    errors and related patient harm: An intervention study. Crit 
    Care 2010;14:R174. 
    13. Klopotowska JE, Wierenga PC, de Rooij SE, Stuijt CC, Arisz 
    L, Kuks PF, et al. The effect of an active on-ward participation 
    of hospital pharmacists in Internal Medicine teams on 
    preventable Adverse Drug Events in elderly inpatients: 
    Protocol of the WINGS study (Ward-oriented pharmacy 
    in newly admitted geriatric seniors). BMC Health Serv Res 
    2011;11:124.
    14. Kunac DL, Reith DM. Identification of priorities for medication 
    safety in neonatal intensive care. Drug Saf 2005;28:251-61.
    15. Folli HL, Poole RL, Benitz WE, Russo JC. Medication error 
    prevention by clinical pharmacists in two children’s hospitals. 
    Pediatrics 1987;79:718-22.
    16. Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, 
    Federico F, et al. Medication errors and adverse drug events 
    in pediatric inpatients. JAMA 2001;285:2114-20.
    17. Ross LM, Wallace J, Paton JY. Medication errors in a pediatric 
    teaching hospital in the UK: Five years operational experience. 
    Arch Dis Child 2000;83:492-7.
    18. Lowry JA, Vandover JC, DeGreeff J, Scalzo AJ. Unusual 
    presentation of iatrogenic phenytoin toxicity in a newborn. J 
    Med Toxicol 2005;1:26-9.
    19. Kohn LT, Corrigan JM, Donaldson MS. To Err Is Human. 
    Washington, DC: National Academy Press; 2000.
    20. Yanni S. Disposition and Interaction of Bio therapeutics in 
    Pediatric Populations. Curr Drug Metab 2012 [In press].
    21. Levine SR, Cohen MR, Blanchard NR, Frederico F, Magelli M, 
    Lomax C, et al. Guidelines for preventing medication errors 
    in pediatrics. J Pediatr Pharmacol Ther 2001;6:426-42. 
    22. Kelishadi R, Hashemipour M, Adeli K, Tavakoli N, 
    Movahedian-Attar A, Shapouri J, et al. Effect of zinc 
    supplementation on markers of insulin resistance, oxidative 
    stress, and inflammation among prepubescent children with 
    metabolic syndrome. Metab Syndr Relat Disord 2010;8:505-10. 
    23. Rezvanian H, Hashemipour M, Kelishadi R, Tavakoli N, 
    Poursafa P. A randomized, triple masked, placebo-controlled 
    clinical trial for controlling childhood obesity. World J Pediatr 
    2010;6:317-22.
    24. Hashemipour M, Kelishadi R, Shapouri J, Sarrafzadegan N, 
    Amini M, Tavakoli N, et al. Effect of zinc supplementation on 
    insulin resistance and components of the metabolic syndrome in 
    pre pubertal obese children. Hormones (Athens) 2009;8:279-85. 
    25. Rashed AN, Wong IC, Cranswick N, Tomlin S, Rascher W, 
    Neubert A. Risk factors associated with adverse drug reactions 
    in hospitalised children: international multicentre study. Eur 
    J Clin Pharmacol 2012;68:801-10.
    26. Matsubara K, Toyama A, Satoh H, Suzuki H, Awaya T, Tasaki Y, 
    et al. Longer working hours of pharmacists in the ward 
    resulted in lower medication-related errors−survey of national 
    university hospitals in Japan. Yakugaku Zasshi 2011;131:635-41.
    27. Bond CA, Raehl CL, Franke T. Clinical pharmacy services and 
    hospital mortality rates. Pharmacotherapy 1999;19:556-64.
    28. Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, 
    Erickson JI, et al. Pharmacist participation on physician rounds 
    and adverse drug events in the intensive care unit. JAMA 
    1999;282:267-70.
    29. Zhang C, Zhang L, Huang L, Luo R, Wen J. Clinical 
    pharmacists on medical care of pediatric inpatients: A singlecenter randomized controlled trial. PLoS One 2012;7:e30856.
    30. Academic Health Centers. Leading Change in the 21st Century. 
    Washington, DC: National Academy Press; 2003.
    31. Koren G. Trends of medication errors in hospitalized children. 
    J Clin Pharmacol 2002;42:707-10.
    32. Kunac DL, Kennedy J, Austin N, Reith D. Incidence, 
    preventability, and impact of Adverse Drug Events (ADEs) 
    and potential ADEs in hospitalized children in New Zealand: 
    a prospective observational cohort study. Paediatr Drugs 
    2009;11:153-60.
    33. Fernandez-Llamazares CM, Calleja-Hernández MA, 
    Manrique-Rodríguez S, Pérez-Sanz C, Durán-García E, 
    Sanjurjo-Sáez M. Prescribing errors intercepted by clinical 
    pharmacists in paediatrics and obstetrics in a tertiary hospital 
    in Spain. Eur J Clin Pharmacol 2012 [In Press]. 
    34. Kunac DL, Kennedy J, Austin N, Reith D. Incidence, 
    preventability, and impact of Adverse Drug Events (ADEs) 
    and potential ADEs in hospitalized children in New Zealand: 
    a prospective observational cohort study. Paediatr Drugs 
    2009;11:153-60. 
    35. Robinson RF. Hospital pharmacists’ role in the prevention and 
    management of respiratory syncytial virus. Am J Health Syst 
    Pharm 2008;65(23 Suppl 8):S20-2. 
    36. Kennedy MJ, Phan H, Benavides S, Potts A, Sorensen S. The 
    role of the pediatric pharmacist in personalized medicine 
    and clinical pharmacogenomics for children: pediatric 
    pharmacogenomics working group. J Pediatr Pharmacol Ther 
    2011;16:118-22.
    37. Kaushal R, Bates DW, Abramson EL, Soukup JR, Goldmann 
    DA. Unit-based clinical pharmacists’ prevention of serious 
    medication errors in pediatric inpatients. Am J Health Syst 
    Pharm 2008;65:1254-60.
    38. Ito S, Nakamura H, Kobayashi T. Pediatric Pharmacology in 
    Japan. Paediatr Drugs 2012;14:247-9.
    39. Leong R, Vieira ML, Zhao P, Mulugeta Y, Lee C, Huang SM, 
    et al. Regulatory experience with physiologically based 
    pharmacokinetic modeling for pediatric drug trials. Clin 
    Pharmacol Ther 2012;91:926-31.
Journal of Research in Pharmacy Practice
Volume 1, Issue 1
August 2012
Pages 10-13

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us